Cherry Health and Michigan State University College of Human Medicine, Grand Rapids, MI, USA.
Alkermes, Inc., Waltham, MA, USA.
BMC Psychiatry. 2018 Sep 12;18(1):292. doi: 10.1186/s12888-018-1856-y.
Despite the availability of numerous antipsychotic medications, many patients with schizophrenia continue to experience side effects that contribute to the overall burden of the illness. The present survey of patients with schizophrenia and schizoaffective disorder aimed to assess patient attitudes toward antipsychotic treatment, and understand key factors about willingness to try a new medication.
A cross-sectional survey was administered to 250 patients with a primary clinical diagnosis of a schizophrenia spectrum disorder across five outpatient clinics in the United States. The survey included self-reported gender, age, weight, and height, and questions about the importance of efficacy and side effects on the decision to take a prescribed antipsychotic medication.
Patients rated efficacy and side effects as important attributes of antipsychotic treatment, with 93.6% and 83.6% of patients listing these as "very" or the "most" important factors in taking prescribed medication. A total of 87.6% of respondents identified the ability to think more clearly as an important property of their medication. Patients identified weight gain, physical restlessness, and somnolence as important side effects of current treatments ("very" or "most" important by 61.6%, 60.8%, and 58.8%, respectively). When asked about willingness to change antipsychotic medication, anticipated weight gain had a negative influence on willingness to try the new treatment, with 22.0% declining to try a medication that would lead to weight gain of 2.7-4.5 kg (6-10 lb), 34.0% declining for anticipated weight gain of 5.0-9.1 kg (11-20 lb), and 52.4% declining for anticipated weight gain greater than 9 kg (20 lbs).
Patients living with schizophrenia spectrum disorders are influenced by many factors when considering whether to take their medication, including efficacy and side effects. It is important for clinicians to assess specific patient concerns to develop a comprehensive treatment plan that maximizes adherence to the prescribed therapy.
尽管有许多抗精神病药物可供使用，但许多精神分裂症患者仍会出现副作用，从而加重疾病负担。本项针对精神分裂症和分裂情感障碍患者的调查旨在评估患者对抗精神病治疗的态度，并了解尝试新药物的意愿的关键因素。
在美国的五个门诊诊所中，对 250 名具有精神分裂症谱系障碍主要临床诊断的患者进行了横断面调查。该调查包括患者自我报告的性别、年龄、体重和身高，以及关于疗效和副作用对决定服用规定的抗精神病药物的重要性的问题。
患者认为疗效和副作用是抗精神病治疗的重要属性，93.6%和 83.6%的患者将这些因素列为服用规定药物的“非常”或“最重要”因素。共有 87.6%的受访者认为思维更清晰是其药物的重要特性。患者将体重增加、身体不安和嗜睡确定为当前治疗的重要副作用（分别为 61.6%、60.8%和 58.8%的患者认为这些副作用“非常”或“最重要”）。当被问及是否愿意改变抗精神病药物时，预期的体重增加对尝试新治疗的意愿产生了负面影响，有 22.0%的患者拒绝尝试可能导致体重增加 2.7-4.5kg（6-10 磅）的药物，34.0%的患者拒绝体重增加 5.0-9.1kg（11-20 磅）的药物，52.4%的患者拒绝体重增加超过 9kg（20 磅）的药物。
当考虑是否服用药物时，患有精神分裂症谱系障碍的患者会受到许多因素的影响，包括疗效和副作用。临床医生评估特定患者的关注点对于制定最大程度地提高对规定治疗的依从性的综合治疗计划非常重要。
